Nalbuphine ER
Protocol 182018 (TR10)
Phase 1 small_molecule completed
Quick answer
Nalbuphine ER for Hepatic Impairment is a Phase 1 program (small_molecule) at Trevi Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Trevi Therapeutics
- Indication
- Hepatic Impairment
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- completed